Mediwound Stock News

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, b

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair a

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 17 2022.

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and

MediWound (MDWD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a t

DBV Technologies DBVT +16%. EyePoint Pharmaceuticals (EYPT) +14%. NuCana (NCNA) -54%. MediWound (MDWD) -15%.

MediWound (MDWD) plunged 17.9% premarket after pricing its underwritten public offering of 5.2M shares at a public offering price of $1.92/share.Gross proceeds are expected to…

MediWound (MDWD), a commercial-stage pharmaceutical company focused on tissue repair and regeneration, has lost ~29% in the post-market Wednesday after announcing a proposed…

YAVNE, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“Mediwound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, b

YAVNE, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair an

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Research Project Award is for the Development of NexoBrid as a Non-Surgical Solution for Field Care Research Project Award is for the Development of NexoBrid as a Non-Surgical Solution for Field Care

YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and

YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD ), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in February. Details for each is as follows: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Date: Wednesday, February 16, 2022 Time: 8:30 am ET Format: Fireside Chat Registration Link: Click here Aegis Virtual Investor Conference Date: Thursday, February 24, 2022 Time: 3:00 pm ET Link: Aegis Virtual Conference Calendar A replay of the fireside chat and presentation will be … Full story available on Benzinga.com

YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and r